Search

Search Results

• 

  Rapid effectiveness of certolizumab pegol in non-radiographic axial spondyloarthritis

  A. Spadaro, A. Scarno, A. Carboni, F.M. Perrotta, C. Catalano, E. Lubrano, G. Valesini

  134-137

  24-07-2013

  https://doi.org/10.4081/reumatismo.2013.134

  2857

  PDF: 827
• 

  Possible relationship between certolizumab pegol and arrhythmias: report of two cases

  R. Talotta, F. Atzeni, A. Batticciotto, D. Ventura, P. Sarzi-Puttini

  104-108

  09-09-2016

  https://doi.org/10.4081/reumatismo.2016.869

  1906

  PDF: 1098
• 

  Retention rate and predictor factors of drug discontinuation in axial spondyloarthritis: a focus on certolizumab and secukinumab

  Ebru Atalar, Hatice Ecem Konak, Pınar Akyüz Dağlı, Bahar Özdemir Ulusoy, Özlem Karakaş, Kevser Orhan, Rezan Koçak Ulucaköy, Esra Kayacan Erdoğan, Serdar Can Güven, Orhan Küçükşahin, İsmail Doğan, Hakan Babaoğlu, Yüksel Maraş, Şükran Erten, Ahmet Omma, Berkan Armağan

  26-06-2025

  https://doi.org/10.4081/reumatismo.2025.1792

  2110

  PDF: 208

• PO:07:099 | Survival on therapy of certolizumab pegol in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: 8-year data from an Italian multicenter register Maria Manara¹, Gilberto Cincinelli^1|2, Marco Fornaro³, Simone Perniola⁴, Elisa Gremese⁵, Chiara Bazzani⁶, Serena Bugatti⁷, Francesca Romana Spinelli⁸, Rosario Foti⁹, Marco Sebastiani¹⁰, Alberto Cauli¹¹, Fabiola Atzeni¹², Giovanni Lapadula¹³, Gianfranco Ferraccioli¹⁴, Fabrizio Conti⁸, Florenzo Iannone³, Roberto Caporali^1|2 | ¹Department of Rheumatology and Medical Sciences, ASST G. Pini-CTO Milano; ²Department of Clinical Sciences and Community Health, University of Milan; ³Department of Precision and Regenerative Medicine and Ionian Area, University of Bari; ⁴Clinical Immunology Division, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma; ⁵Rheumatology and Clinical Immunology, IRCCS Humanitas Research Hospital, Rozzano (MI); ⁶Unit of Rheumatology and Clinical Immunology, ASST Spedali Civili Brescia; ⁷Department of Internal Medicine and Therapeutics, Università di Pavia; ⁸Rheumatology Unit, Dipartimento Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza University, Roma; ⁹Rheumatology Unit, San Marco Hospital, Policlinico University of Catania; ¹⁰Rheumatology Unit, AUSL Piacenza, University of Parma; ¹¹UOC di Reumatologia, Dipartimento di Scienze Mediche e Sanità Pubblica, Azienda Ospedaliero-Universitaria di Cagliari; ¹²Rheumatology Unit, Department of Experimental and Internal Medicine, University of Messina; ¹³Gruppo Italiano di Studio sulla Early Arthritis, GISEA, Bari; ¹⁴Department of Medicine, Università Cattolica del Sacro Cuore, Fondazione IRCCS Policlinico Gemelli, Roma, Italy

  Società Italiana di Reumatologia

  25-11-2025

  https://doi.org/10.4081/reumatismo.2025.2137

  146
• 

  The use of tumor necrosis factor inhibitors during high-risk pregnancies in antiphospholipid syndrome: a clinical report of a patient with concomitant Takayasu arteritis and case-based review

  Liala Moschetti, Francesca Crisafulli, Francesca Regola, Rossana Orabona, Sofia Pitsigavdaki, Franco Franceschini, Laura Andreoli, Sonia Zatti, Angela Tincani

  29-07-2025

  https://doi.org/10.4081/reumatismo.2025.1835

  1470

  PDF: 173